Literature DB >> 23341522

Competing roads to larynx preservation.

Everett E Vokes.   

Abstract

Mesh：

Year:  2013        PMID： 23341522     DOI： 10.1200/JCO.2012.45.8976

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Comparison of three different concurrent chemoradiation regimens for treatment of laryngeal cancer.

Authors:  Utku Aydil; Müge Akmansu; Özge Gumusay; Faruk Kadri Bakkal; Ömer Yazıcı; Yusuf Kızıl; Ahmet Köybaşıoğlu; Ramazan Yıldız; Süleyman Büyükberber; Erdoğan İnal
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12-18       Impact factor: 2.503

2.  Differential molecular response of larynx cancer cell lines to combined VPA/CDDP treatment.

Authors:  Ewelina Gumbarewicz; Przemko Tylżanowski; Jarogniew Łuszczki; Joanna Kałafut; Arkadiusz Czerwonka; Justyna Szumiło; Anna Wawruszak; Krzysztof Kupisz; Krzysztof Polberg; Jolanta Smok-Kalwat; Andrzej Stepulak
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

3.  Retrospective analysis of the clinical efficacy of definitive chemoradiotherapy for patients with hypopharyngeal cancer.

Authors:  Keiichi Takehana; Takeshi Kodaira; Hiroyuki Tachibana; Kana Kimura; Arisa Shimizu; Chiyoko Makita; Natsuo Tomita; Daisuke Nishikawa; Hidenori Suzuki; Hitoshi Hirakawa; Nobuhiro Hanai; Yasuhisa Hasegawa
Journal:  Jpn J Clin Oncol       Date:  2016-01-29       Impact factor: 3.019

4.  Definitive radiation therapy for treatment of laryngeal carcinoma: impact of local relapse on outcome and implications for treatment strategies.

Authors:  F Hoebers; E Rios; E Troost; P van den Ende; K Kross; M Lacko; R Lalisang; B Kremer; J de Jong
Journal:  Strahlenther Onkol       Date:  2013-08-24       Impact factor: 3.621

5.  Tumor Volumes and Prognosis in Laryngeal Cancer.

Authors:  Mohamad R Issa; Stuart E Samuels; Emily Bellile; Firas L Shalabi; Avraham Eisbruch; Gregory Wolf
Journal:  Cancers (Basel)       Date:  2015-11-10       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.